Cardiovascular and neurological toxicity of venlafaxine

被引:43
作者
Blythe, D
Hackett, LP
机构
[1] Sir Charles Gairdner Hosp, Intens Care Unit, Perth, WA 6009, Australia
[2] Western Australian Ctr Pathol & Med Res, Clin Pharmacol & Toxicol Lab, Perth, WA 6009, Australia
关键词
venlafaxine; cardiotoxicity; neurotoxicity; pharmacokinetics;
D O I
10.1191/096032799678840165
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
1 We report a case of venlafaxine overdose and describe pharmacokinetic data on drug disposition. 2 Case report. Serial venlafaxine levels were measured and drug half-life calculated and compared to data at therapeutic concentrations. Metabolite concentrations were also measured and the potential for toxicity described with reference to individual variation in such metabolism 3 Venlafaxine can cause significant cardiac and neurotoxicity. Its potential for causing such toxicity may be dependent on whether an individual has the extensive metaboliser cytochrome CYP2D6 phenotype or the poor metaboliser phenotype.
引用
收藏
页码:309 / 313
页数:5
相关论文
共 21 条
[1]   Fatal venlafaxine overdose [J].
Benham, NDG .
MEDICAL JOURNAL OF AUSTRALIA, 1998, 169 (08) :445-+
[2]   GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19 [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1995, 29 (03) :192-209
[3]   A DOUBLE-BLIND COMPARISON OF VENLAFAXINE AND FLUOXETINE IN PATIENTS HOSPITALIZED FOR MAJOR DEPRESSION AND MELANCHOLIA [J].
CLERC, GE ;
RUIMY, P ;
VERDEAUPAILLES, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1994, 9 (03) :139-143
[4]   Venlafaxine overdose [J].
Coorey, AN ;
Wenck, DJ .
MEDICAL JOURNAL OF AUSTRALIA, 1998, 168 (10) :523-523
[5]   A CASE-REPORT OF VENLAFAXINE TOXICITY [J].
FANTASKEY, A ;
BURKHART, KK .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1995, 33 (04) :359-361
[6]  
Feighner JP, 1995, J CLIN PSYCHIAT, V56, P574
[7]   VENLAFAXINE - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC POTENTIAL IN DEPRESSION [J].
HOLLIDAY, SM ;
BENFIELD, P .
DRUGS, 1995, 49 (02) :280-294
[8]   INTRODUCTION OF A COMPOSITE PARAMETER TO THE PHARMACOKINETICS OF VENLAFAXINE AND ITS ACTIVE O-DESMETHYL METABOLITE [J].
KLAMERUS, KJ ;
MALONEY, K ;
RUDOLPH, RL ;
SISENWINE, SF ;
JUSKO, WJ ;
CHIANG, ST .
JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (08) :716-724
[9]  
Llett KF, 1998, BRIT J CLIN PHARMACO, V45, P459, DOI 10.1046/j.1365-2125.1998.00710.x
[10]   VENLAFAXINE - A STRUCTURALLY UNIQUE AND NOVEL ANTIDEPRESSANT [J].
MORTON, WA ;
SONNE, SC ;
VERGA, MA .
ANNALS OF PHARMACOTHERAPY, 1995, 29 (04) :387-395